



# ESGCT General Assembly

21<sup>st</sup> October  
Florence, Italy



## AGENDA

- Society Financials
- New initiatives
- Membership
- Board Elections
- Florence congress overview
- Next congress – Berlin
- Questions / AOB



# SOCIETY FINANCIALS

# End-of-year available cash

	<i>EOY in bank</i>	<i>safety buffer</i>	<i>remaining</i>
2012	€ 133,000.00	€ 100,000.00	€ 33,000.00
2013	€ 188,000.00	€ 100,000.00	€ 88,000.00
2014	€ 114,000.00	€ 100,000.00	€ 14,000.00
2015	€ 168,000.00	€ 100,000.00	€ 68,000.00
2016	€ 283,500.00	€ 150,000.00	€ 183,500.00

- As congresses and the society grows, importance to ensure financial buffer
- Main aims always to improve dissemination of information, support of studentship, share science

# Spend 2016

- Congress 2016
- Board, Membership, Office Administration
- Spring School 2016
- Support of national society meetings: €2500 DG-GT
- Support of national society meetings: €2500 SFTCG
- Support of national society initiatives: €2500 SETGyC
- Website development
- Data system development
- Award structure development
- Social media and digital communication development

# Planned Spend 2017

- Congress 2017
- Spring School 2017
- Support of national society meetings: €2500 BSGCT
- Support of national society meetings: €2500 NVGCT
- New website launch
- Blog and curated news launch
- Data system development including congress logistics
- New Award structure launch
- Social media and digital communication development
- Scoping additional support needs of ESGCT members  
e.g. standard guidance docs, specialist bio hacks.

# NEW WEBSITE

EUROPEAN SOCIETY OF  
GENE & CELL THERAPY



EUROPEAN SOCIETY OF  
GENE & CELL THERAPY



Login | Register



Home

About ESGCT -

Useful Information -

Congress -

Sponsorship -

Membership -

News and Events -

Awards -

Contact



The European Society of Gene and Cell Therapy (ESGCT) promotes basic and clinical research in gene therapy, cell therapy, and genetic vaccines by facilitating education, the exchange of information and technology and by serving as a professional adviser to stakeholder communities and regulatory bodies in Europe.

amet consectetur

et, consectetur adipiscing elit, sed diam nonummy nibh euismod tincidunt ut laoreet dolore magna  
visi enim ad minim veniam, quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea  
autem vel eum iriure dolor in hendrerit in vulputate velit esse molestie consequat. [Register today](#)



EVENTS

Click here for Events



MEMBERSHIP

Click here to join us



AWARDS

Ut wisi enim ad minim veniam, quis  
nostrud exerci tation ullamcorper  
suscipit lobortis



OTHER

Ut wisi enim ad minim veniam, quis  
nostrud exerci tation ullamcorper  
suscipit lobortis

Latest News

Upcoming Events

Jobs & Courses

# MEMBER INITIATIVES:

## NEW WEBSITE

EUROPEAN SOCIETY OF  
GENE & CELL THERAPY



- **Blog**
- **Subject-specific Forum**
- **Curated Headline News Stories**
- **Job market:** available postings, postings sought
- **Internship market:** available postings, postings sought
- **News:** recycling and reposting of stories in the media



# NEW AWARDS!



- Honorarium for regular bloggers and vloggers
- Science Communication
- Mentor
- Public Engagement
- Excellence Awards for abstract authors in addition to Travel Grant Awards



# MEMBERSHIP

# MEMBERSHIP

	2016	2015	2014	2013
	961	528	422	463
Academic	55%	30%	43%	42%
Students	20%	49%	45%	45%
Industrial	25%	21%	12%	13%

# MEMBERSHIP

EUROPEAN SOCIETY OF  
GENE & CELL THERAPY



Italy	17%	Iran	1%
United Kingdom	12%	Finland	1%
France	12%	Portugal	1%
United States	11%	Israel	1%
Germany	9%	Sweden	1%
Spain	6%	Canada	1%
Japan	3%	Australia	1%
South Korea	3%	Thailand	1%
Turkey	2%	Brazil	1%
Switzerland	2%	South Africa	1%
Austria	2%	Mexico	1%
Belgium	2%	Denmark	1%
Russian Federation	2%		

**Less than 1%:** Poland, Korea, Netherlands, Latvia, Ireland, India, United Arab Emirates, Ukraine, Slovakia (Slovak Republic), Saudi Arabia, Malaysia, Iraq, Hungary, Greece, China, Argentina, Uruguay, Taiwan, Singapore, Republic of Korea, Qatar, Norway, Luxembourg, Lithuania, Gambia, Cyprus, Albania



# BOARD ELECTIONS

# BOARD ELECTIONS

EUROPEAN SOCIETY OF  
GENE & CELL THERAPY



**We have one position to fill.**

**The candidate with the most votes is:**

**Vincenzo Cerullo**

**Thank you to the nominees and everyone who voted. We encourage you to apply again as the vote was very close!**

## **Executive Board**

**Hildegard Büning**: Vice-President (to follow Robin Ali as President)



# FLORENCE CONGRESS OVERVIEW

# Registrations

- 1341 registrations

Academic member	441
N/member	243
Industry member	159
N/member	277
Student	221



# TOPLINE NUMBERS

- **1341** registrations
- **57** exhibitors, **76** sponsors in total
- **10** travel awards
- **1** Outstanding Achievement Award
- **1** Young Investigator Award
- **93** Invited speakers
- **63** Selected orals
- **461** Posters
- And **countless** new collaborations!

# Registrations

Italy	233
United States	214
United Kingdom	149
France	117
Germany	96
Spain	72
Japan	49
Switzerland	33
South Korea	30
Austria	26
The Netherlands	25
Belgium	21
Russian Federation	19
Turkey	17
Portugal	12
Canada	11
Finland	11
Iran	11
Denmark	10

Australia	9
Israel	9
Sweden	9
Taiwan	9
Korea	7
Brazil	6
Greece	5
Mexico	5
South Africa	5
Thailand	5
China	4
Czech Republic	4
Latvia	3
Poland	3
Qatar	3
India	2
Ireland	2
Luxembourg	2
Norway	2

Singapore	2
Slovakia (Slovak Republic)	2
Ukraine	2
Albania	1
Cyprus	1
Egypt	1
Estonia	1
Hong Kong	1
Iraq	1
Italia	1
Republic of Korea	1
Saudi Arabia	1
Uruguay	1



25th Anniversary Meeting  
of the ESGCT  
in collaboration with the DG-GT  
17-20 October 2017 | Berlin

**Keynote speakers:**

Chris Baum, Jef Boeke, Nathalie Cartier-Lacave

**Plenary speakers include:**

John Bell, Thomas Blankenstein, Malcolm Brenner, Frank Buchholz, Juan Bueren, Laurence Cooper, Michele de Luca, Stefanie Diemmler, Giuliana Ferrari, Keith Joung, Juergen Knoblich, Andras Nagy, Adrian Thrasher

**Parallel speakers include:**

Eric Alton, Marinee Chuah, Giulio Cossu, Krithika Hariharan, Michael Hudecek, Eugenio Montini, Rosario Perona, Waseem Qasim, Axel Schambach, Len Seymour, Gabriele Thumann, Hans Dieter Volk, Christof von Kalle, David Williams, Guy Ungerechts

**Plenary sessions on:**

Highlight of clinical progress  
Stem cells: biology, manipulation and reprogramming  
Cancer immuno-gene therapy  
New tools and technology: gene and genome editing and engineering  
Gene and cell therapy in the market

**Parallel sessions on:**

iPS disease modelling  
Ocular and central nervous system gene and cell therapy  
Oncolysis  
Gene editing  
Cardiovascular, muscle and pulmonary gene and cell therapy  
Vector development  
Regenerative therapies  
Metabolic and lysosomal storage diseases  
Cancer predisposition, ageing and genetic instability syndromes  
Blood disorders  
Cancer gene therapy



# QUESTIONS / AOB